日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics

利用群体药代动力学选择伊沙妥昔单抗治疗儿童白血病患者的给药方案

Brillac, Claire; Sémiond, Dorothée; Oprea, Corina; Baruchel, André; Zwaan, C Michel; Nguyen, Laurent

Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

在多发性骨髓瘤患者中,通过暴露-反应分析选择/确认伊沙妥昔单抗联合泊马度胺/地塞米松治疗的最佳给药方案

Rachedi, Fatiha; Koiwai, Kimiko; Gaudel-Dedieu, Nadia; Sebastien, Bernard; Thai, Hoai-Thu; Brillac, Claire; Fau, Jean Baptiste; Nguyen, Laurent; van de Velde, Helgi; Veyrat-Follet, Christine; Semiond, Dorothée

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

一项针对达雷妥尤单抗耐药的多发性骨髓瘤患者的伊沙妥昔单抗单药治疗的 II 期研究

Mikhael, Joseph; Belhadj-Merzoug, Karim; Hulin, Cyrille; Vincent, Laure; Moreau, Philippe; Gasparetto, Cristina; Pour, Ludek; Spicka, Ivan; Vij, Ravi; Zonder, Jeffrey; Atanackovic, Djordje; Gabrail, Nashat; Martin, Thomas G; Perrot, Aurore; Bensfia, Samira; Weng, Qilong; Brillac, Claire; Semiond, Dorothée; Macé, Sandrine; Corzo, Kathryn P; Leleu, Xavier

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

对伊沙妥昔单抗单药及联合治疗多发性骨髓瘤患者进行PK/PD模型分析,以确定给药方案。

Koiwai, Kimiko; El-Cheikh, Raouf; Thai, Hoai-Thu; Brillac, Claire; Fau, Jean-Baptiste; Veyrat-Follet, Christine; Risse, Marie-Laure; van de Velde, Helgi; Semiond, Dorothée; Nguyen, Laurent

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

一项针对复发/难治性多发性骨髓瘤的单药isatuximab(抗CD38单克隆抗体)剂量探索性II期研究

Mikhael, Joseph; Richter, Joshua; Vij, Ravi; Cole, Craig; Zonder, Jeffrey; Kaufman, Jonathan L; Bensinger, William; Dimopoulos, Meletios; Lendvai, Nikoletta; Hari, Parameswaran; Ocio, Enrique M; Gasparetto, Cristina; Kumar, Shaji; Oprea, Corina; Chiron, Marielle; Brillac, Claire; Charpentier, Eric; San-Miguel, Jesús; Martin, Thomas

Nuclear control of lung cancer cells migration, invasion and bioenergetics by eukaryotic translation initiation factor 3F

真核翻译起始因子 3F 对肺癌细胞迁移、侵袭和生物能量的核控制

Pauline Esteves, Laetitia Dard, Aurélia Brillac, Christophe Hubert, Saharnaz Sarlak, Benoît Rousseau, Elodie Dumon, Julien Izotte, Marc Bonneu, Didier Lacombe, Jean-William Dupuy, Nivea Amoedo, Rodrigue Rossignol

Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients

伊沙妥昔单抗在复发/难治性多发性骨髓瘤患者中的药物-疾病相互作用和时间依赖性群体药代动力学

Fau, Jean-Baptiste; El-Cheikh, Raouf; Brillac, Claire; Koiwai, Kimiko; Mace, Nathalie; Campana, Frank; Semiond, Dorothee; Nguyen, Laurent

Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer

阿柏西普联合FOLFIRI方案作为二线治疗方案治疗日本转移性结直肠癌患者的II期临床试验

Denda, Tadamichi; Sakai, Daisuke; Hamaguchi, Tetsuya; Sugimoto, Naotoshi; Ura, Takashi; Yamazaki, Kentaro; Fujii, Hirofumi; Kajiwara, Takeshi; Nakajima, Takako Eguchi; Takahashi, Shin; Otsu, Satoshi; Komatsu, Yoshito; Nagashima, Fumio; Moriwaki, Toshikazu; Esaki, Taito; Sato, Takeo; Itabashi, Michio; Oki, Eiji; Sasaki, Toru; Sunaga, Yoshinori; Ziti-Ljajic, Samira; Brillac, Claire; Yoshino, Takayuki